Methods for treating subjects having a CXC chemokine receptor 5 (CXCR5)-responsive cancer by administering fully human anti-CXCR5 antibodies
There is disclosed compositions and methods relating to or derived from anti-CXCR5 antibodies. More specifically, there is disclosed fully human antibodies that bind CXCR5, CXCR5-binding fragments and derivatives of such antibodies, and CXCR5-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having CXCR5 related disorders or conditions, including various inflammatory disorders and various cancers.
1. A method for treating a subject having a C-X-C Motif Chemokine Receptor 5 (CXCR5)-positive cancer, said method comprising administering an effective amount of an anti-CXCR5 polypeptide to a subject in need thereof, wherein the anti-CXCR5 polypeptide is selected from the group consisting of a recombinant fully human anti-CXCR5 antibody that binds to CXCR5, a recombinant fully human anti-CXCR5 antibody Fab fragment, and a recombinant anti-CXCR5 single chain antibody, wherein the anti-CXCR5 polypeptide comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO. 108, and comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO. 109.
2. The method of claim 1 , wherein the recombinant fully human anti-CXCR5 antibody is classified as an isotype selected from the group consisting of: IgG, IgM, IgD, IgA, and IgE.
3. The method of claim 2 , wherein the IgG isotype antibody is an IgG1 or an IgG4.
4. The method of claim 1 , wherein the recombinant fully human anti-CXCR5 antibody, or an antigen-binding fragment thereof, is classified as an isotype selected from the group consisting of: IgG, IgM, IgD, IgA, and IgE.
5. The method of claim 1 , wherein the CXCR5-positive cancer is selected from the group consisting of colorectal cancer, head and neck cancer, small cell lung cancer, non-small cell lung cancer (NSCLC), pancreatic cancer, bladder cancer, blood cancer, bone cancer, brain cancer, breast cancer, cartilage cancer, colon cancer, endometrial cancer, gastric cancer, kidney cancer, liver cancer, lung cancer, lymph node cancer, nervous tissue cancer, ovarian cancer, pancreatic cancer, prostate cancer, skeletal muscle cancer, skin cancer, spinal cord cancer, spleen cancer, stomach cancer, testes cancer, thymus cancer, thyroid cancer, tracheal cancer, urogenital tract cancer, ureter cancer, urethral cancer, uterine cancer and vaginal cancer.